行情

BLPH

BLPH

柏勒罗丰治疗
NASDAQ

实时行情|Nasdaq Last Sale

8.36
-0.49
-5.54%
盘后: 8.37 +0.01 +0.12% 16:08 02/27 EST
开盘
8.93
昨收
8.85
最高
8.93
最低
7.73
成交量
10.23万
成交额
--
52周最高
11.98
52周最低
3.260
市值
3,829.08万
市盈率(TTM)
-0.2461
分时
5日
1月
3月
1年
5年

分析师评级

2位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测

分析师预测BLPH价格均价为30.00,最高价位30.00,最低价为30.00。

EPS

BLPH 新闻

更多
  • Amarin's Upgrade, And Other News: The Good, Bad And Ugly Of Biopharma
  • Seeking Alpha - Article · 3天前
  • The Week Ahead In Biotech: Biopharma Earnings Pick Up Pace
  • Benzinga · 3天前
  • The One Metric That Helps Me Find Stocks With The Greatest Potential
  • Benzinga · 6天前
  • The One Metric That Helps Me Find Stocks With The Greatest Potential
  • Benzinga · 6天前

所属板块

生物技术和医学研究
-3.79%
制药与医学研究
-3.00%

热门股票

代码
价格
涨跌幅
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%

BLPH 简况

Bellerophon Therapeutics, Inc. is a clinical-stage therapeutics company. The Company is focused on developing products at the intersection of drugs and devices that address medical needs in the treatment of cardiopulmonary diseases. The Company is focused on the development of its nitric oxide therapy for patients with pulmonary hypertension (PH), using its delivery system, INOpulse, with pulmonary arterial hypertension (PAH) as the lead indication. Its INOpulse device has a mechanism that delivers brief, targeted pulses of nitric oxide timed to occur at the beginning of a breath for delivery to the alveoli of the lungs, which minimizes the amount of drug required for treatment. The Company's second program, BCM, is a medical device focused to prevent congestive heart failure following a ST Segment Elevation Myocardial Infarction (STEMI), which is a type of severe heart attack. The Company's BCM is in PRESERVATION I clinical trial.
展开

微牛提供Bellerophon Therapeutics Inc(NASDAQ-BLPH)的股票价格,实时市场报价,专业分析师评级,深度图表和免费的BLPH股票新闻,以帮助您做出投资决策。